| NCT00914732 | Smallpox | Biological: MVA Smallpox Vaccine|Biological: MVA Smallpox Vaccine|Biological: MVA Smallpox Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2010-02-01 | 2014-12-04 |
| NCT00879762 | Variola Major (Smallpox) | Biological: IMVAMUNE庐 High Dose|Drug: Placebo|Biological: IMVAMUNE庐 Standard Dose | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2009-05-01 | 2012-12-06 |
| NCT01466738 | Healthy | Biological: HRV-16 (100 TCID50)|Biological: HRV-16 (1000 TCID50) | Centocor Ortho Biotech Services, L.L.C. | Phase 1 | 2011-09-01 | 2012-02-20 |
| NCT00565929 | Variola Major (Smallpox) | Drug: Placebo|Biological: MVA-BN | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2008-09-01 | 2013-08-01 |
| NCT00508651 | Healthy | Biological: MEDI-560|Biological: Placebo | MedImmune LLC | Phase 1|Phase 2 | 2007-10-01 | 2011-11-28 |
| NCT02824965 | Non-Small Cell Lung Cancer | Drug: Pembrolizumab|Biological: CVA21 | Olivia Newton-John Cancer Research Institute|Merck Sharp & Dohme Corp.|Viralytics | Phase 1 | 2016-07-01 | 2016-07-10 |
| NCT00386633 | HIV Infections | Biological: MVA-mBN32|Biological: MVA-mBN32 | Bavarian Nordic | Phase 1 | 2006-10-01 | 2015-01-26 |
| NCT02419391 | Respiratory Syncytial Virus Infections | Biological: MVA BN RSV|Other: Placebo | Bavarian Nordic | Phase 1 | 2015-08-01 | 2016-08-09 |
| NCT00390078 | HIV Infections | Biological: MVA-mBN32|Biological: IMVAMUNE | Bavarian Nordic|National Institutes of Health (NIH) | Phase 1|Phase 2 | 2007-01-01 | 2009-07-09 |
| NCT02977715 | Monkeypox Virus Infection | Biological: IMVAMUNE庐 | Centers for Disease Control and Prevention|Ministry of Public Health, Democratic Republic of the Congo|Kinshasa School of Public Health|Bavarian Nordic | Phase 3 | 2017-02-23 | 2017-02-27 |
| NCT00651157 | Recurrent Melanoma|Stage IV Melanoma | Biological: wild-type reovirus | National Cancer Institute (NCI) | Phase 2 | 2008-04-01 | 2014-03-21 |
| NCT01491893 | GBM|Glioblastoma|Glioma|Malignant Glioma | Biological: PVSRIPO | Darell D. Bigner, MD, PhD|National Cancer Institute (NCI)|Brain Tumor Research Charity Grant|Duke University | Phase 1 | 2012-01-01 | 2017-03-21 |
| NCT01866306 | Asthma | Biological: RV16UB|Drug: LABA | Merck Sharp & Dohme Corp.|U-BIOPRED Consortium | Phase 1 | 2013-10-01 | 2017-01-23 |
| NCT00493285 | Respiratory Viral Infections|Respiratory Syncytial Virus Infections|Parainfluenza Virus 3, Human | Biological: MEDI-534|Biological: MEDI-534|Biological: MEDI-534 | MedImmune LLC | Phase 1 | 2007-07-01 | 2012-07-13 |
| NCT01078701 | Influenza, Human | Biological: GHB11L1|Biological: Placebo | AVIR Green Hills Biotechnology AG | Phase 2 | 2009-12-01 | 2011-01-04 |
| NCT01922284 | HIV | Biological: DNA|Biological: MVA-C|Biological: CN54rgp140|Biological: GLA-AF | Imperial College London|Medical Research Council|Wellcome Trust | Phase 1 | 2013-06-01 | 2016-09-26 |
| NCT01827371 | Smallpox | Biological: MVA Smallpox Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2013-06-01 | 2016-07-28 |
| NCT03028441 | Chikungunya Virus Infection | Biological: Chikungunya vaccine|Other: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | null | 2017-03-02 |
| NCT00724997 | Seasonal Human Influenza | Biological: GHB01L1 | AVIR Green Hills Biotechnology AG | Phase 1 | 2007-03-01 | 2009-12-07 |
| NCT02755948 | Respiratory Syncytial Virus Infections|Influenza, Human | Biological: RSV A Memphis 37|Biological: Influenza A/California/04/2009 | Imperial College London|Medical Research Council|Wellcome Trust|National Institute for Health Research, United Kingdom | | 2012-04-01 | 2016-04-26 |
| NCT00316524 | Smallpox | Biological: MVA-BN庐 (IMVAMUNE)|Biological: IMVAMUNE|Biological: IMVAMUNE|Biological: IMVAMUNE | Bavarian Nordic|National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2006-05-01 | 2015-06-02 |
